Cmed Technology Allows BioPharma to Speed Study Setup While Using Fewer Resources

Cmed Technology Allows BioPharma to Speed Study Setup While Using Fewer Resources

Timaeus Guided Trial Builder breaks the two-week trial build barrier without sacrificing flexibility, quality or adherence to best practices

NEW PROVIDENCE, N.J., Oct. 27, 2011 /PRNewswire/ -- Cmed Technology, an innovative provider of eClinical technology, announced today the launch of Timaeus Guided Trial Builder (GTB), a new product that introduces an entirely different approach to reduce the time and effort required to start up electronic trials. GTB builds on a decade of real-world experience managing trials in Cmed's CRO division. GTB enables study teams to speed up and simplify Study Setup-without sacrificing flexibility, quality or adherence to best practices.

A new survey of 55 large pharmaceutical companies, small biotechs, CROs and non-profit organizations indicates the current industry trial build process takes too long.(1) All respondents indicated the trial build process typically takes weeks or months to complete; not a single organization indicated an average trial build time shorter than two weeks. The next most common complaints were that the build process: requires too much technical knowledge; is too complicated; does not sufficiently comply with standards; and requires too much work to ensure quality control. "BioPharmaceutical and research companies want eClinical technology to let them manage more trials with greater speed, higher quality and without increasing resources," said Cmed CEO Dr. David Connelly. "The survey data confirms that the traditional industry trial build tools-after years of trying-do not satisfy these needs. Timaeus Guided Trial Builder addresses the goal of the quick, easy and validated electronic trial with a different approach, one that brings a top-down, validated Web 2.0 model to the eClinical world."

Central to GTB is the Maximal Re-use Template (MRT) approach, which encompass all the common factors and best practices across a sponsor's portfolio and places them in one large validated "super page." MRTs enable rapid build of complete trials-including visit schedules, pages and complex edit checks-without any need of technical programming knowledge. They automatically ensure adherence to standards and seamlessly validate the trial during the build process, eliminating the need for manual quality control (QC) and hand-offs between teams. Adding Guided Trial Builder to Timaeus' on-demand deployment capabilities allows study teams to start new trials and perform mid-trial updates at the touch of a button-without downtime or site interruption.

Over the next month, Cmed will be demonstrating Timaeus Guided Trial Builder in three cities: Basking Ridge, NJ (Thursday, November 10); Durham, NC (Tuesday, November 15); and South San Francisco (Thursday, November 17). Those who attend will be able to build, validate and conduct UAT of fully working electronic trials in minutes while enjoying cocktails and hors d'oeuvres. For more information, or to join one of the events, visit http://www.cmedtechnology.com/GTB-info/.

(1) Survey of 55 large pharmaceutical companies, biotechnology firms, small and large Contract Research Organizations (CROs), non-profit research institutes and charities at the DIA 2011 Annual Meeting and SCDM 2011 Conference.

About Cmed Technology

Cmed Technology is an innovative provider of eClinical technology and solutions. Its unified eClinical platform, Timaeus, combines advanced distributed cloud, mobile and tablet computing technologies to provide research organizations the freedom to manage any type of data, for any trial, anywhere. Timaeus has been used by biopharmaceutical companies, non-profit institutions, CROs and other research organizations for early phase, pivotal and late phase studies. Timaeus provides on-demand solutions for programming of simple, complex and adaptive trials (Timaeus Trial Builder); electronic data capture (Timaeus Electronic Data Capture); monitoring (Timaeus Field Monitoring); in-stream coding (Timaeus Medical Coding); electronic, paper, and hybrid trial data management (Timaeus Electronic Data Management); and clinical and operational reporting (Timaeus Reporting). A division of the Cmed Group with roots from the University of Oxford, Cmed Technology has offices in the United Kingdom, the United States and Romania. To learn more, visit http://www.cmedtechnology.com.

Media Contacts:
Cmed Technology
Christopher Leary
[email protected] or +1 908-795-2006

CHEN PR
Juli Greenwood
[email protected] or +1 781-672-3137

SOURCE Cmed Technology

 

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.